Carsten Schwarz

List of Publications by Year
in descending order

44	1,005	567281 15	454955 30
papers	citations	h-index	g-index

47	47	47	1782
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell, 2019, 176, 1340-1355.e15.	28.9	321
2	Aspergillus Bronchitis in Patients with Cystic Fibrosis. Mycopathologia, 2018, 183, 61-69.	3.1	65
3	Prospective multicenter German study on pulmonary colonization with Scedosporium /Lomentospora species in cystic fibrosis: Epidemiology and new association factors. PLoS ONE, 2017, 12, e0171485.	2.5	47
4	Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 99-107.	0.7	46
5	Hypersensitivity to antibiotics in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 205-211.	0.7	45
6	Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis. Mycopathologia, 2018, 183, 21-32.	3.1	43
7	Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis. Mycopathologia, 2018, 183, 7-19.	3.1	32
8	Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Scientific Reports, 2020, 10, 18999.	3.3	30
9	Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. Medical Mycology, 2018, 56, S42-S59.	0.7	27
10	Invasive Pulmonary Fungal Infections in Cystic Fibrosis. Mycopathologia, 2018, 183, 33-43.	3.1	27
11	Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 227-232.	0.7	26
12	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis, 2021, 20, 228-233.	0.7	21
13	Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections. Mycopathologia, 2018, 183, 213-226.	3.1	17
14	Type I interferon induced by TLR2-TLR4-MyD88-TRIF-IRF3 controls Mycobacterium abscessus subsp. abscessus persistence in murine macrophages via nitric oxide. International Journal of Medical Microbiology, 2019, 309, 307-318.	3.6	16
15	Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis. Pediatric Allergy and Immunology, 2016, 27, 597-603.	2.6	15
16	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1909-1930.e4.	3.8	15
17	Genetic diversification of persistent Mycobacterium abscessus within cystic fibrosis patients. Virulence, 2021, 12, 2415-2429.	4.4	14
18	ColobreatheÂ® for the Treatment of Cystic Fibrosis-Associated Pulmonary Infections. Pulmonary Therapy, 2015, 1, 19-30.	2.2	13

#	Article	IF	Citations
19	Mepolizumabâ€"a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatric Allergy and Immunology, 2018, 29, 28-33.	2.6	13
20	Cystic fibrosis in Europe: patients live longer but are we ready?. European Respiratory Journal, 2015, 46, 11-12.	6.7	11
21	Clinical manifestations and risk factors of arthropathy in cystic fibrosis. Respiratory Medicine, 2019, 147, 66-71.	2.9	11
22	GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). Journal of Cystic Fibrosis, 2020, 19, 292-298.	0.7	11
23	Mutation on lysX from Mycobacterium avium hominissuis impacts the hostâ€"pathogen interaction and virulence phenotype. Virulence, 2020, 11, 132-144.	4.4	11
24	CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. Pulmonary Therapy, 2021, 7, 377-393.	2.2	11
25	Patient experience in cystic fibrosis care: Development of a disease-specific questionnaire. Chronic Illness, 2015, 11, 108-125.	1.5	10
26	Arxula adeninivorans causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. Lancet, The, 2015, 385, 1476.	13.7	10
27	Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2022, 21, 136-142.	0.7	10
28	Scedosporium apiospermum: a fungal pathogen causing pneumonia in a patient with cystic fibrosis. JMM Case Reports, 2015, 2, .	1.3	10
29	Fungal Respiratory Infections in Cystic Fibrosis (CF): Recent Progress and Future Research Agenda. Mycopathologia, 2018, 183, 1-5.	3.1	9
30	Risk of piperacillinâ€induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. Transfusion, 2019, 59, 3746-3754.	1.6	9
31	Prospective Evaluation of Aspergillus fumigatus-Specific IgG in Patients With Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 602836.	3.9	8
32	Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis. BMJ Case Reports, 2016, 2016, bcr2016216937.	0.5	8
33	Cystic fibrosis (CF) care through the patients' eyes â€" A nationwide survey on experience and satisfaction with services using a disease-specific questionnaire. Respiratory Medicine, 2015, 109, 79-87.	2.9	7
34	Environmental Mycobacterium avium subsp. hominissuis have a higher probability to act as a recipient in conjugation than clinical strains. Plasmid, 2018, 95, 28-35.	1.4	7
35	Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. Journal of Cystic Fibrosis, 2021, 20, 1035-1039.	0.7	7
36	Urban Life as Risk Factor for Aspergillosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 601834.	3.9	6

#	Article	IF	Citations
37	Frequent Pet Contact as Risk Factor for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 601821.	3.9	5
38	Biatrial Remodeling in Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2019, 8, 1141.	2.4	3
39	Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging. Pharmaceutics, 2021, 13, 2051.	4.5	3
40	Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. PLoS ONE, 2016, 11, e0158193.	2.5	2
41	Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis. Clinical and Translational Allergy, 2014, 4, P66.	3.2	0
42	Different approaches to evaluate patient experience and satisfaction in CF centres. Journal of Cystic Fibrosis, 2015, 14, E19-E20.	0.7	0
43	Long needed guidelines: Referral to transplant for cystic fibrosis patients. Journal of Cystic Fibrosis, 2019, 18, 305-306.	0.7	0
44	Zystische Fibrose: Mukoviszidose ist lÃngst keine Kinderkrankheit mehr. , 0, , .		0